ESMO: European Society for Medical Oncology

Conference Coverage

OAK: Atezolizumab grows OS in advanced NSCLC

COPENHAGEN – The checkpoint inhibitor atezolizumab improved overall survival of advanced non–small-cell lung cancer, compared with docetaxel.

Pages